Safety of MT-401-OTS in Patients With Relapsed AML or MDS
← catalyst calendarNCT06552416 · readout ≤ 1,138 d
Sponsored by Marker Therapeutics, Inc. (industry) · MRKR — their whole pipeline →. With University of Kansas Medical Center, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, FDA Office of Orphan Products Development.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-16 | actual | When the study began enrolling |
| Primary completion | Sep 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia, in Relapse
- MDS
Intervention
- Drug: MT-401-OTS
Primary outcomes
what the primary-completion date above is the date OFSafety of MT-401-OTS
measured Through study completion. Approximately 5 years
Tolerability of MT-401-OTS
measured Through study completion. Approximately 5 years
Permalink · MRKR's whole pipeline · Catalyst calendar · Every registered study · What changed